HG 205
Alternative Names: HG-205Latest Information Update: 11 Nov 2023
At a glance
- Originator HuidaGene Therapeutics
- Class Gene therapies; RNA
- Mechanism of Action OTOF protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hearing loss
Most Recent Events
- 06 Sep 2023 HuidaGene Therapeutics plans the early phase I SOUND trial for Hearing loss (In Children, In adolescents, In infants) in China (Intracochlear, Injection) (NCT06025032)
- 05 Sep 2023 Preclinical trials in Hearing loss in China (Otic), prior to September 2023 (HuidaGene Therapeutics pipeline, September 2023)